{"id":"https://openalex.org/W3045697709","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.5107","title":"OP0205 PHASE I STUDY OF D-0120, A NOVEL URAT1 INHIBITOR IN CLINICAL DEVELOPMENT FOR HYPERURICEMIA AND GOUT","display_name":"OP0205 PHASE I STUDY OF D-0120, A NOVEL URAT1 INHIBITOR IN CLINICAL DEVELOPMENT FOR HYPERURICEMIA AND GOUT","publication_year":2020,"publication_date":"2020-06-01","ids":{"openalex":"https://openalex.org/W3045697709","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.5107","mag":"3045697709"},"language":"en","primary_location":{"id":"doi:10.1136/annrheumdis-2020-eular.5107","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.5107","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2020-eular.5107","pdf_url":"https://ard.bmj.com/content/annrheumdis/79/Suppl_1/127.2.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ard.bmj.com/content/annrheumdis/79/Suppl_1/127.2.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026266610","display_name":"L. Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268094","display_name":"InventisBio Co., Ltd. (China)","ror":"https://ror.org/05s4wn714","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405268094"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"L. Zhang","raw_affiliation_strings":["InventisBio, Florham Park, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"InventisBio, Florham Park, United States of America","institution_ids":["https://openalex.org/I4405268094"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062164676","display_name":"David J. Wyatt","orcid":"https://orcid.org/0000-0003-0636-9725","observed_orcids":["https://orcid.org/0000-0003-0636-9725"]},"institutions":[{"id":"https://openalex.org/I4210105783","display_name":"Syneos Health (United States)","ror":"https://ror.org/01r74wp43","country_code":"US","type":"company","lineage":["https://openalex.org/I4210105783"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Wyatt","raw_affiliation_strings":["Syneos Health, Miami, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Syneos Health, Miami, United States of America","institution_ids":["https://openalex.org/I4210105783"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043447622","display_name":"K. Stazzone","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268094","display_name":"InventisBio Co., Ltd. (China)","ror":"https://ror.org/05s4wn714","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405268094"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"K. Stazzone","raw_affiliation_strings":["InventisBio, Florham Park, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"InventisBio, Florham Park, United States of America","institution_ids":["https://openalex.org/I4405268094"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Z. Shi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268094","display_name":"InventisBio Co., Ltd. (China)","ror":"https://ror.org/05s4wn714","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405268094"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Z. Shi","raw_affiliation_strings":["InventisBio, Florham Park, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"InventisBio, Florham Park, United States of America","institution_ids":["https://openalex.org/I4405268094"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5101702119","display_name":"Ying Wang","orcid":"https://orcid.org/0000-0001-9038-4762","observed_orcids":["https://orcid.org/0000-0001-9038-4762"]},"institutions":[{"id":"https://openalex.org/I4405268094","display_name":"InventisBio Co., Ltd. (China)","ror":"https://ror.org/05s4wn714","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405268094"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Y. Wang","raw_affiliation_strings":["InventisBio, Florham Park, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"InventisBio, Florham Park, United States of America","institution_ids":["https://openalex.org/I4405268094"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":null,"fwci":0.3139,"has_fulltext":true,"cited_by_count":3,"citation_normalized_percentile":{"value":0.56647538,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"79","issue":null,"first_page":"127","last_page":"128"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11139","display_name":"Gout, Hyperuricemia, Uric Acid","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11117","display_name":"Drug-Induced Adverse Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/urat1-inhibitor","display_name":"URAT1 inhibitor","score":0.9879999756813049},{"id":"https://openalex.org/keywords/uric-acid-transporters","display_name":"uric acid transporters","score":0.7599999904632568},{"id":"https://openalex.org/keywords/hyperuricemia","display_name":"hyperuricemia","score":0.9850000143051147},{"id":"https://openalex.org/keywords/gout","display_name":"gout","score":1.0},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7149999737739563},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9829999804496765},{"id":"https://openalex.org/keywords/febuxostat","display_name":"febuxostat","score":0.7829999923706055},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9810000061988831},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.7089999914169312},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6759999990463257},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.7129999995231628},{"id":"https://openalex.org/keywords/lesinurad","display_name":"lesinurad","score":0.8080000281333923},{"id":"https://openalex.org/keywords/urate-lowering-therapy","display_name":"urate-lowering therapy","score":0.5329999923706055}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7944952249526978},{"id":"https://openalex.org/C2780402116","wikidata":"https://www.wikidata.org/wiki/Q133087","display_name":"Gout","level":2,"score":0.7226539850234985},{"id":"https://openalex.org/C2779721657","wikidata":"https://www.wikidata.org/wiki/Q49970","display_name":"Hyperuricemia","level":3,"score":0.6797884702682495},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4351252615451813},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42442435026168823},{"id":"https://openalex.org/C2779881121","wikidata":"https://www.wikidata.org/wiki/Q105522","display_name":"Uric acid","level":2,"score":0.39455240964889526}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/annrheumdis-2020-eular.5107","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.5107","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2020-eular.5107","pdf_url":"https://ard.bmj.com/content/annrheumdis/79/Suppl_1/127.2.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1136/annrheumdis-2020-eular.5107","doi":"https://doi.org/10.1136/annrheumdis-2020-eular.5107","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2020-eular.5107","pdf_url":"https://ard.bmj.com/content/annrheumdis/79/Suppl_1/127.2.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320321798","display_name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","ror":"https://ror.org/00y6khe77"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3045697709.pdf","grobid_xml":"https://content.openalex.org/works/W3045697709.grobid-xml"},"referenced_works_count":1,"referenced_works":["https://openalex.org/W3043885468"],"related_works":["https://openalex.org/W2982080084","https://openalex.org/W2321289833","https://openalex.org/W7203630700","https://openalex.org/W3001927088","https://openalex.org/W4391262473","https://openalex.org/W2764084587","https://openalex.org/W4411395673","https://openalex.org/W2991369588","https://openalex.org/W2529475680","https://openalex.org/W4401399080"],"abstract_inverted_index":null,"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-08-03T00:00:00"}